Pharmaceutical hits in 2016


Pharmaceutical hits in 2016 (Image courtesy of amenic181 at


Analysts from EvaluatePharma selected drugs currently under review by FDA which have the biggest chance to pay off by 2020. Here we present the summary of top 10.

Ocrelizumab, Roche ($2.7 billion in 2020) - for relapsing/remitting as well as primary progressive multiple sclerosis.
Atezolizumab, Roche ($2.5 billion in 2020) - for broad applications in oncology.
Grazoprevir/elbasvir, Merck ($1.9 billion in 2020) - for hepatitis C.
Dupilumab, Regeneron/Sanofi ($1.8 billion in 2020) - for eczema and asthma.
Obeticholic acid, Intercept Pharmaceuticals ($1.6 billion in 2020) - for primary biliary cirrhosis.
Venetoclax, AbbVie/Roche ($1.4 billion in 2020) - for chronic lymphocytic leukemia.
Emtricitabine/Tenofovir Alafenamide Fumarate, Gilead ($1.3 billion in 2020) - for HIV.
Empliciti, Bristol-Myers Squibb/AbbVie ($1.08 billion in 2020) - for multiple myeloma.
Uptravi, Actelion ($1.08 billion in 2020) - for pulmonary arterial hypertension.
Ixekizumab, Eli Lilly ($1.03 billion in 2020) - for psoriasis.

Report: Evaluate Pharma
Image credits: amenic181
Image source:
Feel free to contact us.


Phone: +48 71 725 34 10

Office address
ul. E. Kwiatkowskiego 4, 52-326 Wrocław, Poland

© 2020 - Grupa Kapitałowa Startit Fund | All rights reserved.

Made in:

Important: I hereby confirm that I have read the Privacy Policy and Cookies Policy of Startit Fund Sp. z o.o. [Ltd.] company
Join us!